Impact of Artificial Intelligence-Enhanced Insertable Cardiac Monitors on Device Clinic Workflow and Resource Utilization
- PMID: 40107046
- PMCID: PMC11968260
- DOI: 10.1016/j.jacadv.2025.101656
Impact of Artificial Intelligence-Enhanced Insertable Cardiac Monitors on Device Clinic Workflow and Resource Utilization
Abstract
Background: Insertable cardiac monitors (ICMs) are essential for managing arrhythmias but often generate large numbers of transmissions and false alerts. Integrating artificial intelligence (AI) as part of the ICM workflow can reduce this burden. However, its impact on clinic workflow and resource utilization must be better understood.
Objectives: The aim of the study was to assess the impact of AI-enhanced ICMs on clinic workflow and resource utilization.
Methods: A cross-sectional analysis was conducted using real-world, deidentified ICM remote monitoring data from Octagos Health, which included 140 U.S. device clinics between July 2022 and April 2024. Nonactionable alerts (NAAs) were defined as false or repetitive alerts transmitted on the remote monitoring platforms but dismissed by device technicians and not forwarded to clinicians for review. We compared NAAs generated by AI-enhanced vs non-AI-enhanced ICMs and estimated associated staffing hours, resources, and costs extrapolated for a clinic managing 600 ICM patients.
Results: Among 19,320 patients (mean age: 69 ± 13.5 years; 47.3% male), 68% had non-AI-enhanced ICMs, and 32% had AI-enhanced ICMs. The mean annual NAA volume per 600-ICM clinic was 5,078 for non-AI-enhanced ICMs and 2,110 for AI-enhanced ICMs, resulting in 559 fewer staffing hours (956 vs 397 hours; 95% CI: 513-605 hours; P value < 0.001) and $29,470 in annual savings ($20,929 vs $50,399; 95% CI: $27,035-$31,904; P value < 0.001).
Conclusions: Compared to non-AI-enhanced ICMs, AI-enhanced ICMs significantly reduce NAAs, leading to a projected decrease in clinic workload and associated costs, potentially improving workflow and health care efficiency.
Keywords: AI; artificial intelligence; cardiac arrhythmias; health economics; insertable cardiac monitors; remote monitoring.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding support and author disclosures The open access fee was funded by Medtronic. Drs Colombowala and Bansal are shareholders of Octagos Health. Dr Pothineni is a consultant for Medtronic and Biosense Webster. Dr Gopinathannair is a consultant for Boston Scientific. Dr Lakkireddy is a consultant for Abbott Vascular, Biotronik, BioSense Webster, Medtronic, Boston Scientific, Atricure, Acutus, and Northeast Scientific. Dr Kabra is a consultant for Volta Medical. Ms Rosemas and Mr Higuera are employees and shareholders of Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures




References
-
- Joglar J.A., Chung M.K., Armbruster A.L., et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024;149:e1–e156. - PMC - PubMed
-
- Ferrick A.M., Raj S.R., Deneke T., et al. 2023 HRS/EHRA/APHRS/LAHRS expert consensus statement on practical management of the remote device clinic. Heart Rhythm. 2023;20:e92–e144. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous